Transphorm downgraded to Hold from Buy at Benchmark

Benchmark analyst David Williams downgraded Transphorm to Hold from Buy following the announced agreement for an acquisition by Renesas last week. While the firm had predicted a transaction was the most likely outcome from the strategic review process initiated last year, it is “disappointed” by the $5.10 per share, or $339M, valuation, the analyst tells investors.